Transform how you analyse drug development risk
With the only transparent analysis of drug development risk at the product level.
LONDON, BOSTON, SAN FRANCISCO, TOKYO (June 13, 2017) — Life science commercial intelligence firm, Evaluate, is launching their annual complimentary industry report, “EvaluatePharma World Preview 2017, Outlook to 2022” at the annual BIO International Convention in San Diego, June 19-22, 2017, Booth #3627.
The report, which sets the industry standard for consensus forecasts for the life sciences, provides an overview of the sector including key trends, patent expiry impact, top products and companies, R&D spend and consensus forecasts to 2022. Complimentary copies of the executive summary will be available in the Evaluate Booth #3627. Follow @evaluatepharma on Twitter to receive download link for the full report on release date June 20th or visit www.evaluate.com.
The Evaluate team will also showcase key new data sets and analyses designed to support faster and more accurate asset screening, appraisal and forecasting for their clients high value decisions, including:
In attendance to discuss the report findings and latest analyses will be Anthony Raeside, Head of Research; Antonio Iervolino, Head of Forecasting; Andy Williams, Head of Product Management and Paul Verdin, PhD Head of Custom Services. Staff from the UK, Japan and US offices will also be in attendance. Meetings can be scheduled by going to www.evaluate.com or through the BIO Partnering system, or simply stop by the Evaluate Booth #3627 where there is a private meeting space.
Evaluate provides trusted commercial intelligence for the pharmaceutical and medical device industries.
Our EvaluatePharma® online subscription services provides a seamless view of the past, present and future of the global pharmaceutical market in a single, standardised platform.
Vantage – our award-winning, independent editorial team – provides thought-provoking news and insights into the current and future developments in the industry.
Evaluate has been a partner to industry-leading organisations for over 20 years. For more information on how we give our clients the time and understanding to drive better decisions, visit www.evaluate.com.